Pharmadrug Inc. (LMLLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pharmadrug Inc. (LMLLF) with AI Score 48/100 (Weak). Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled substances and natural medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Pharmadrug Inc. (LMLLF) Healthcare & Pipeline Overview
Pharmadrug Inc. is a specialty pharmaceutical company focusing on the research, development, and commercialization of controlled substances and natural medicines, including psychedelics and cannabis. The company imports medical cannabis to the EU and researches natural medicines, positioning itself within the evolving landscape of alternative therapies.
Investment Thesis
Pharmadrug Inc. presents a speculative investment opportunity within the emerging market for psychedelic and cannabis-based pharmaceuticals. The company's research agreements with the University of Michigan and Johns Hopkins University, focusing on DMT, represent potential catalysts for future growth. The company's distribution of medical cannabis in Germany and the EU provides an existing revenue stream, though the company's market capitalization of $0.00B indicates significant risk. A P/E ratio of -4.44 reflects current losses, suggesting the company is in a high-growth, pre-profitability phase. The company's beta of 0.46 suggests lower volatility than the overall market. Success hinges on the clinical trial outcomes, regulatory approvals, and market acceptance of its products.
Based on FMP financials and quantitative analysis
Key Highlights
- Pharmadrug Inc. focuses on the research, development, and commercialization of controlled substances and natural medicines, including psychedelics and cannabis.
- The company imports and distributes medical cannabis to pharmacies in Germany and the rest of the European Union, providing an established revenue stream.
- Pharmadrug has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness.
- The company has a clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing the effects of DMT.
- Pharmadrug operates with a team of 9 employees, reflecting its focus on research and development.
Competitors & Peers
Strengths
- Focus on emerging markets such as psychedelics and medical cannabis.
- Research agreements with reputable universities and research institutions.
- Established distribution network for medical cannabis in Europe.
- Proprietary research and development capabilities.
Weaknesses
- Limited financial resources and small market capitalization.
- Reliance on regulatory approvals and clinical trial outcomes.
- Limited number of employees.
- Negative P/E ratio indicates unprofitability.
Catalysts
- Upcoming: Clinical trial results from the Johns Hopkins University study on DMT.
- Upcoming: Regulatory approvals for medical cannabis products in new European markets.
- Ongoing: Expansion of the Super Smart product line.
- Ongoing: Progress in the research and development of cepharanthine.
- Ongoing: Strategic partnerships and acquisitions.
Risks
- Potential: Clinical trial failures for DMT-based therapies.
- Potential: Changes in regulations regarding cannabis and psychedelics.
- Potential: Competition from larger pharmaceutical companies.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Dependence on key personnel and research agreements.
Growth Opportunities
- Growth opportunity 1: Expansion of Medical Cannabis Distribution in the EU: Pharmadrug can leverage its existing distribution network in Germany and the EU to expand its reach to other countries as regulations evolve. The European cannabis market is projected to reach €3.2 billion by 2025, offering a substantial growth opportunity. Success depends on navigating complex regulatory frameworks and establishing strong relationships with local pharmacies and healthcare providers.
- Growth opportunity 2: Development and Commercialization of DMT-Based Therapies: Pharmadrug's research agreements with the University of Michigan and Johns Hopkins University position it to develop novel DMT-based therapies for mental health disorders. The market for psychedelic-assisted therapies is projected to grow rapidly, driven by increasing acceptance of these treatments. The timeline for commercialization depends on clinical trial outcomes and regulatory approvals.
- Growth opportunity 3: Super Smart Functional Mushroom Product Line Expansion: Pharmadrug's Super Smart entity focuses on functional and psilocybin mushrooms. Expanding this product line could tap into the growing market for functional foods and natural health products. The global functional mushroom market is projected to reach $34.3 billion by 2024. Success requires effective marketing and product development.
- Growth opportunity 4: Cepharanthine Manufacturing and Clinical Trials: Pharmadrug's agreement with Southwest Research Institute to manufacture cepharanthine opens opportunities for clinical trials and potential commercialization of this compound. Cepharanthine has shown potential in treating various conditions, including cancer and viral infections. The timeline depends on clinical trial results and regulatory approvals.
- Growth opportunity 5: Strategic Partnerships and Acquisitions: Pharmadrug can accelerate its growth through strategic partnerships and acquisitions. Collaborating with other companies in the pharmaceutical, biotechnology, and cannabis industries can provide access to new technologies, markets, and expertise. Identifying and acquiring complementary businesses can expand Pharmadrug's product portfolio and market reach.
Opportunities
- Expansion of medical cannabis distribution to other European countries.
- Development and commercialization of novel DMT-based therapies.
- Growth of the functional mushroom market.
- Strategic partnerships and acquisitions.
Threats
- Changing regulatory landscape for cannabis and psychedelics.
- Competition from larger pharmaceutical companies.
- Clinical trial failures.
- Difficulty in securing funding for research and development.
Competitive Advantages
- Proprietary research and development capabilities in the area of controlled substances and natural medicines.
- Established distribution network for medical cannabis in Germany and the EU.
- Strategic partnerships with leading universities and research institutions.
- Focus on innovative therapies and emerging markets, such as psychedelics.
About LMLLF
Pharmadrug Inc., formerly known as Aura Health Inc., was rebranded in October 2019 to reflect its strategic shift towards specialty pharmaceuticals. The company focuses on the research, development, and commercialization of controlled substances and natural medicines, including psychedelics, cannabis, and naturally-derived approved drugs. Pharmadrug imports and distributes medical cannabis to pharmacies in Germany and the rest of the European Union, capitalizing on the growing acceptance and legalization of cannabis for medical purposes. The company also owns and operates Super Smart, an entity focused on elevating the use of functional and psilocybin mushrooms. Pharmadrug is actively involved in researching and reformulating established natural medicines, seeking to identify new applications and improve existing treatments. The company has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness. Additionally, Pharmadrug has an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine and a clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. Based in Toronto, Canada, Pharmadrug operates with a team of 9 employees, reflecting its focus on research and development activities.
What They Do
- Researches and develops controlled substances and natural medicines.
- Focuses on psychedelics, cannabis, and naturally-derived approved drugs.
- Imports and distributes medical cannabis to pharmacies in Germany and the EU.
- Operates Super Smart, focused on functional and psilocybin mushrooms.
- Researches and reformulates established natural medicines.
- Conducts clinical trials to evaluate the effects of DMT.
Business Model
- Generates revenue through the import and distribution of medical cannabis.
- Develops and commercializes novel pharmaceutical products based on controlled substances and natural medicines.
- Conducts research and development activities under agreements with universities and research institutions.
- Operates Super Smart, focused on functional and psilocybin mushrooms.
Industry Context
Pharmadrug Inc. operates within the specialty pharmaceutical and emerging psychedelic medicine industries. These sectors are characterized by rapid innovation, evolving regulatory landscapes, and increasing interest in alternative therapies. The global psychedelic medicine market is projected to reach billions of dollars in the coming years, driven by growing acceptance of psychedelics for mental health treatment. Pharmadrug competes with other specialty pharmaceutical companies and firms focused on psychedelic research and development. Competitors include BIOE, CNGGF, CPMD, NRPR, and RAFA. Success in this industry requires strong research capabilities, regulatory expertise, and effective commercialization strategies.
Key Customers
- Pharmacies in Germany and the rest of the European Union that distribute medical cannabis.
- Patients who use medical cannabis and other pharmaceutical products developed by the company.
- Consumers interested in functional and psilocybin mushroom products through Super Smart.
- Research institutions and universities that collaborate with Pharmadrug on research and development projects.
Financials
Chart & Info
Pharmadrug Inc. (LMLLF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Oct 21, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LMLLF.
Price Targets
Wall Street price target analysis for LMLLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates LMLLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Kideckel
CEO
David Kideckel serves as the CEO of Pharmadrug Inc., leading a team of 9 employees. His background includes experience in the healthcare and pharmaceutical industries. He has a track record of working with emerging companies in the life sciences sector. His expertise spans strategic planning, business development, and capital markets. Kideckel's leadership is focused on driving Pharmadrug's research and development efforts and expanding its market presence.
Track Record: Under David Kideckel's leadership, Pharmadrug Inc. has focused on research agreements with the University of Michigan and Johns Hopkins University. He has overseen the company's efforts to develop novel therapies based on controlled substances and natural medicines. He has also guided the company's expansion in the European medical cannabis market. His strategic decisions have positioned Pharmadrug in the emerging psychedelic medicine industry.
LMLLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pharmadrug Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher risk of fraud and manipulation compared to listed exchanges.
- Limited regulatory oversight and investor protection.
- Increased price volatility due to speculative trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capitalization structure and potential dilution.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags or material events.
- Consult with a qualified financial advisor.
- Research agreements with reputable universities such as the University of Michigan and Johns Hopkins University.
- Focus on research and development of pharmaceutical products.
- Established distribution network for medical cannabis in Europe.
- Active participation in industry conferences and events.
- Presence of experienced management team with backgrounds in healthcare and pharmaceuticals.
What Investors Ask About Pharmadrug Inc. (LMLLF)
What does Pharmadrug Inc. do?
Pharmadrug Inc. operates as a specialty pharmaceutical company focused on the research, development, and commercialization of controlled substances and natural medicines. This includes psychedelics, cannabis, and naturally-derived approved drugs. The company imports and distributes medical cannabis to pharmacies in Germany and the rest of the European Union. Pharmadrug also conducts research on established natural medicines and operates Super Smart, an entity focused on functional and psilocybin mushrooms, positioning itself in the evolving landscape of alternative therapies and pharmaceutical innovation.
What do analysts say about LMLLF stock?
AI analysis is currently pending for LMLLF stock. Given its OTC listing and focus on emerging markets like psychedelics and medical cannabis, analyst coverage may be limited. Investors should conduct their own due diligence and carefully evaluate the company's financial condition, research pipeline, and regulatory risks. Key valuation metrics include market capitalization, revenue growth, and cash flow. The speculative nature of the business warrants a cautious approach.
What are the main risks for LMLLF?
Pharmadrug Inc. faces several key risks, including regulatory uncertainty surrounding cannabis and psychedelics, the potential for clinical trial failures, and competition from larger pharmaceutical companies. The company's limited financial resources and reliance on external funding also pose significant challenges. As an OTC-listed company, LMLLF is subject to less stringent regulatory oversight and may experience greater price volatility. Investors should carefully consider these risks before investing in Pharmadrug Inc.
What are the key factors to evaluate for LMLLF?
Pharmadrug Inc. (LMLLF) currently holds an AI score of 48/100, indicating low score. Key strength: Focus on emerging markets such as psychedelics and medical cannabis.. Primary risk to monitor: Potential: Clinical trial failures for DMT-based therapies.. This is not financial advice.
How frequently does LMLLF data refresh on this page?
LMLLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LMLLF's recent stock price performance?
Recent price movement in Pharmadrug Inc. (LMLLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on emerging markets such as psychedelics and medical cannabis.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LMLLF overvalued or undervalued right now?
Determining whether Pharmadrug Inc. (LMLLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LMLLF?
Before investing in Pharmadrug Inc. (LMLLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.